^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Reyobiq (rhenium Re186 obisbemeda)

    i
    Other names: 186RNL, rhenium-186 nanoliposome, rhenium nanoliposome
    Associations

    News

    Trials
    Company:
    NanoTx Therap, Plus Therap
    Drug class:
    Ionizing radiation emitter
    Related drugs:
    Associations

    News

    Trials
    4ms
    CA2024-LM-001: Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases (clinicaltrials.gov)
    P1, N=24, Recruiting, Plus Therapeutics
    New P1 trial
    |
    Reyobiq (rhenium Re186 obisbemeda)
    5ms
    Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma (clinicaltrials.gov)
    P1, N=56, Not yet recruiting, Plus Therapeutics
    New P1 trial
    |
    Reyobiq (rhenium Re186 obisbemeda)
    8ms
    Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment (clinicaltrials.gov)
    P1, N=40, Recruiting, Plus Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Reyobiq (rhenium Re186 obisbemeda)
    8ms
    ReSPECT-LM: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Plus Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Reyobiq (rhenium Re186 obisbemeda)
    8ms
    ReSPECT-GBM: Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) (clinicaltrials.gov)
    P1/2, N=55, Recruiting, Plus Therapeutics | Trial completion date: Jan 2025 --> Dec 2025 | Trial primary completion date: Jan 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    IDH wild-type
    |
    Reyobiq (rhenium Re186 obisbemeda)
    over1year
    Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Plus Therapeutics | Trial completion date: Jan 2025 --> Mar 2028 | Trial primary completion date: Jan 2025 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    Reyobiq (rhenium Re186 obisbemeda)
    over1year
    Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial (GlobeNewswire)
    "Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, 'CNSide' and discussed potential partnering opportunities....Plus presented topline clinical trial data from the FORESEE trial which met its primary endpoint of clinical utility for the CNSide test in 40 patients with LM due to either breast or non-small cell lung cancer; a presentation of the full analysis is planned for the August 8-10 SNO/ASCO Meeting in Denver, CO."
    Licensing / partnership
    |
    CNSide™ Cerebrospinal Fluid Assay
    |
    Reyobiq (rhenium Re186 obisbemeda)
    2years
    Multi-parametric MRI and SPECT Assessment of Treatment Dose and Efficacy in Respect-GBM for recurrent glioblastoma (rGBM) (SNO 2023)
    Background: We have previously shown a dose-dependent association with survival for patients receiving Rhenium-186-nanoliposome (186RNL) for rGBM... MRI radiographic features proved valuable in assessing treatment efficacy and guiding treatment considerations. Image processing is ongoing, and the complete data set will be presented.
    Clinical
    |
    Reyobiq (rhenium Re186 obisbemeda)
    2years
    Rhenium-(Re-186)-obisbemeda [Re-186-nanoliposome] (186RNL) Phase 2 for recurrent glioblastoma (rGBM) via Convection Enhance Delivery [CED] (SNO 2023)
    186RNL therapy resulted in a dose and volume dependent impact on OS without significant toxicity. Based on these data, the Cohort 6 non-DLT dose advanced to Phase 2. Study progress will be reported.
    P2 data
    |
    Reyobiq (rhenium Re186 obisbemeda)
    2years
    Rhenium (Re-186) obisbemeda{Re-186-Nanoliposome (186RNL)} in Leptomeningeal Metastases [LM] Phase 1/2a Dose Escalation Trial: Initial Safety and Feasibility (SNO 2023)
    Adjuvant MHT may induce tumor radio-sensitization, immune cell recruitment, and survival benefit when combined with CRT. Optimization of the combination therapy treatment scheme is required.
    Clinical • P1/2 data
    |
    Reyobiq (rhenium Re186 obisbemeda)
    2years
    Efficacy among therapeutically effective absorbed dose patients in ReSPECT-GBM phase I of rhenium-186 nanoliposome (186RNL) in recurrent glioblastoma (rGBM) compared to an external control arm (ECA) (SNO 2023)
    Based on prior work establishing the comparability of a bevacizumab (Bev) comparator to inform early-phase CED study results, OS of the 15 TAD patients were compared to a Bev ECA. Single-arm studies can be challenging to interpret. By comparing the ReSPECT-GBM outcomes to an ECA of similar patients with balanced baseline characteristics, we can better appreciate the treatment effect of 186RNL administered via CED. The current results are encouraging, and updated results reflecting current follow-up will be presented at the meeting.
    Clinical • P1 data
    |
    Avastin (bevacizumab) • Reyobiq (rhenium Re186 obisbemeda)
    2years
    Update Report of the ReSPECT-GBM Phase I/IIa Dose Escalation Trial of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma [rGBM] via Convection Enhanced Delivery (CED) (SNO 2023)
    A single administration of 186RNL by CED in recurrent glioma patients is feasible, safe, and potentially effective in increasing overall survival when > 100Gy radiation is delivered to the tumor. A RP2D of 22.3mCi in 8.8mL was selected for patients with tumor size of ≤20mL in the planned Phase 2B.
    P1/2 data
    |
    Reyobiq (rhenium Re186 obisbemeda)